Gemfibrozil Tablets

Indicated to target high triglycerides, utilized to manage lipid profiles.

Strengths: 300mg

Medicine details

Alternative names

Lopid

Therapeutic class

Fibrate

Pharmacological class

PPAR Alpha Agonist

Minor side effects

dyspepsia; abdominal pain; diarrhoea

Moderate side effects

dizziness; fatigue; skin rash

Dosage forms

Film-coated tablet

Administration route

Oral use

Patient summary

Indicated to target high triglycerides, utilized to manage lipid profiles.

Prescription status

POM

Manufacturer

Pfizer

Onset Time

3–5 days

Duration

12–24 hours

Storage instructions

Store below 25°C.

Drug interactions

statins; warfarin; repaglinide

Age restrictions

Adults only

Pregnancy and breastfeeding

Pregnancy: Not recommended. Breastfeeding: Avoid during treatment.

Contraindications

hypersensitivity to gemfibrozil; hepatic impairment; severe renal impairment; pre-existing gallbladder disease

Precautions and warnings

regular blood monitoring required; report unexplained muscle pain; monitor liver function

Serious side effects

rhabdomyolysis — requires immediate medical attention; cholelithiasis — requires immediate medical attention

Mechanism of action

Gemfibrozil is a fibrate that acts as a PPAR-alpha agonist. It increases lipolysis and decreases hepatic production of triglyceride-rich lipoproteins, effectively lowering serum triglyceride levels and increasing HDL cholesterol.

Gemfibrozil Tablets

Indicated to target high triglycerides, utilized to manage lipid profiles.

Editorial Notes

  • Active ingredient(s): Gemfibrozil
  • Listed indication(s): Hypertriglyceridaemia

Available option

  • 60 tablets - 300 mg1390-300-mg-16667